Please assess the completion status of the following clinical trial:

Trial Title: Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to MICU with respiratory failure and intubated~* ARDS criteria per Berlin definition~* PaO2:FiO2 ratio ≤ 200 mmHg for \> 6 hours with FiO2 ≥0.5~* Expected to require mechanical ventilation for \>48 hours~* Reversible disease~Exclusion Criteria:~* Anticoagulation contraindicated~* Proven HIT~* Unable to obtain central venous access~* Refractory hypoxia (PaO2:FiO2 ≤80 after recruitment and proning) or other indication for ECMO~* Home oxygen use~* Severe COPD~* Interstitial lung disease~* \> 7 days of mechanical ventilation~* Immunocompromised patient (bone marrow, untreated HIV, PJP)~* Advanced malignancy with life expectancy ≤ 6months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Conventional lung protective ventilation (Type: ACTIVE_COMPARATOR): Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
- Ultra-protective ventilation (Type: EXPERIMENTAL): Ultra-protective ventilation (\</= 3ml/kg predicted body weight) targeting plateau pressure of \</= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).